ATE444741T1 - Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung - Google Patents
Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendungInfo
- Publication number
- ATE444741T1 ATE444741T1 AT06009678T AT06009678T ATE444741T1 AT E444741 T1 ATE444741 T1 AT E444741T1 AT 06009678 T AT06009678 T AT 06009678T AT 06009678 T AT06009678 T AT 06009678T AT E444741 T1 ATE444741 T1 AT E444741T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- spherical microcapsules
- diseases
- conditions associated
- glp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06009678A EP1854455B1 (de) | 2006-05-10 | 2006-05-10 | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE444741T1 true ATE444741T1 (de) | 2009-10-15 |
Family
ID=37773605
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06009678T ATE444741T1 (de) | 2006-05-10 | 2006-05-10 | Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung |
AT07724702T ATE502628T1 (de) | 2006-05-10 | 2007-04-27 | Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07724702T ATE502628T1 (de) | 2006-05-10 | 2007-04-27 | Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung |
Country Status (13)
Country | Link |
---|---|
US (2) | US8790705B2 (de) |
EP (3) | EP1854455B1 (de) |
JP (1) | JP5209608B2 (de) |
CN (1) | CN101489539A (de) |
AT (2) | ATE444741T1 (de) |
AU (1) | AU2007247511B2 (de) |
CA (1) | CA2649902A1 (de) |
DE (2) | DE602006009631D1 (de) |
DK (1) | DK2015736T3 (de) |
ES (1) | ES2363810T3 (de) |
PL (1) | PL2015736T3 (de) |
PT (1) | PT2015736E (de) |
WO (1) | WO2007128443A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1767545E (pt) | 2005-09-22 | 2010-02-05 | Biocompatibles Uk Ltd | Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase |
EP1854455B1 (de) | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
EP1972349A1 (de) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP1975176A1 (de) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP2176400B1 (de) * | 2007-07-11 | 2015-10-14 | Technion Research & Development Foundation Ltd. | Verkapselte mesenchymale stammzellen und verwendungen davon |
EP2163243A1 (de) * | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern |
EP2251028A1 (de) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Behandlung von Augenerkrankungen unter Verwendung eingekapselter Zellen, die einen antiangiogenetischen Faktor und/oder einen neuroprotektiven Faktor codieren und sekretieren |
US20120020931A1 (en) | 2010-06-02 | 2012-01-26 | Rutgers, The State University Of New Jersey | Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells |
US20140004201A1 (en) * | 2010-09-15 | 2014-01-02 | Biocompatibles Uk Ltd. | Treatment of Vascular Diseases Using Encapsulated Cells Encoding and Secreting GLP-1, or a Fragment or Variant Thereof |
EP3834757B1 (de) | 2011-01-19 | 2022-03-09 | Fractyl Health, Inc. | Geräte zur behandlung des dünndarmes |
KR20140051161A (ko) * | 2011-03-29 | 2014-04-30 | 베타-셀 엔브이 | 캡슐화된 치료제의 제조 방법 및 이의 용도 |
CN103619342B (zh) * | 2011-05-19 | 2018-08-10 | 麦瑟布莱斯特公司 | 用于治疗肥胖症和/或代谢综合征的方法 |
KR101335176B1 (ko) * | 2011-12-12 | 2013-11-29 | 테고사이언스 (주) | 상처 치유용 드레싱재제 |
AU2013226062B2 (en) | 2012-02-27 | 2017-10-19 | Fractyl Health, Inc. | Heat ablation systems, devices and methods for the treatment of tissue |
CA2869904C (en) | 2012-04-19 | 2020-04-21 | Fractyl Laboratories, Inc. | Systems for expanding tissue prior to energy ablation |
EP2879605A4 (de) | 2012-07-30 | 2016-04-06 | Fractyl Lab Inc | Stromablationssysteme, vorrichtungen und verfahren zur behandlung von gewebe |
WO2014026055A1 (en) | 2012-08-09 | 2014-02-13 | Fractyl Laboratories Inc. | Ablation systems, devices and methods for the treatment of tissue |
WO2014055997A1 (en) | 2012-10-05 | 2014-04-10 | Fractyl Laboratories Inc. | Methods, systems and devices for performing multiple treatments on a patient |
EP3003461B1 (de) | 2013-06-04 | 2019-05-01 | Fractyl Laboratories, Inc. | Systeme und vorrichtungen zur reduzierung des lumenoberflächenbereichs des gastrointestinaltrakts |
EP3043732B1 (de) | 2013-09-12 | 2021-04-07 | Fractyl Laboratories, Inc. | Systeme und vorrichtungen zur behandlung von zielgewebe |
EP3071286B1 (de) * | 2013-11-22 | 2024-01-03 | Fractyl Health, Inc. | Systeme zur erzeugung einer therapeutischen einschränkung im magen-darm-trakt |
CN104805058A (zh) * | 2014-01-23 | 2015-07-29 | 上海欧易生物医学科技有限公司 | 一种稳定表达外源性glp-1基因的人脐带源间充质干细胞株 |
US10959774B2 (en) | 2014-03-24 | 2021-03-30 | Fractyl Laboratories, Inc. | Injectate delivery devices, systems and methods |
US11185367B2 (en) | 2014-07-16 | 2021-11-30 | Fractyl Health, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
WO2016011269A1 (en) | 2014-07-16 | 2016-01-21 | Fractyl Laboratories, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
US9757535B2 (en) | 2014-07-16 | 2017-09-12 | Fractyl Laboratories, Inc. | Systems, devices and methods for performing medical procedures in the intestine |
TWI726889B (zh) * | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
CN108697768B (zh) | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经***病状和神经退行性病状的治疗方法 |
CN111518770B (zh) * | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
CN111803617A (zh) * | 2020-07-16 | 2020-10-23 | 卡杜兰(广州)生命基因工程科技有限公司 | 一种内载微囊的干细胞***与制备方法 |
US20220389071A9 (en) * | 2020-09-22 | 2022-12-08 | Yang Wei | Long-lasting glp1 analogue drug for type-2 diabetes |
CN113493764B (zh) * | 2021-07-27 | 2023-01-24 | 新乡医学院 | 一种体外诱导小鼠耳朵间充质干细胞分化为脂肪细胞的方法 |
WO2023028554A1 (en) * | 2021-08-25 | 2023-03-02 | Neuraly, Inc. | Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
US6849708B1 (en) * | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
ES2109336T3 (es) | 1990-11-26 | 1998-01-16 | Genetics Inst | Expresion de pace en celulas huesped y metodos de utilizacion de la misma. |
US5270181A (en) | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
EP0499990B1 (de) * | 1991-02-19 | 1996-05-15 | Takeda Chemical Industries, Ltd. | Verfahren zur Herstellung von cysteinfreien Peptiden |
GB9311147D0 (en) | 1993-05-28 | 1993-07-14 | Long Ashton Research Station | Regulation of plant growth |
KR100611130B1 (ko) | 1996-03-01 | 2006-11-30 | 노보 노르디스크 에이/에스 | 식욕억제펩티드로이루어진약학적조성물의사용 |
PT966297E (pt) * | 1996-08-08 | 2009-03-18 | Amylin Pharmaceuticals Inc | Regulação da motilidade gastrintestinal |
US5830723A (en) | 1996-08-13 | 1998-11-03 | Regents Of The University Of Minnesota | Method for immortalizing chicken cells |
JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
ATE366584T1 (de) | 1996-11-12 | 2007-08-15 | Novo Nordisk As | Verwendung von glp-1 peptiden |
WO1999035242A1 (en) | 1998-01-12 | 1999-07-15 | Betagene, Inc. | Media for neuroendocrine cells |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
WO1999053064A2 (en) * | 1998-04-13 | 1999-10-21 | Modex Therapeutiques, S.A. | Methods of delivering glp-1 |
DE19836960A1 (de) | 1998-08-14 | 2000-02-17 | Ulrich Zimmermann | Verfahren zur Gewinnung hochgereinigter Alginate |
US7259136B2 (en) * | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
DE19904785A1 (de) | 1999-02-05 | 2000-08-10 | Ulrich Zimmermann | Verfahren zur Herstellung von stabilem Alginatmaterial |
US6267954B1 (en) * | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
ES2253353T3 (es) | 2000-03-08 | 2006-06-01 | Novo Nordisk A/S | Reduccion del colesterol serico. |
EP1355942B1 (de) | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteine |
EP1401480B1 (de) | 2001-02-22 | 2012-11-28 | Novartis AG | Für endostatin kodierende virale vektoren zur behandlung von okularer neovaskularisation |
ATE382057T1 (de) * | 2001-06-28 | 2008-01-15 | Novo Nordisk As | Stabile formulierung von modifiziertem glp-1 |
CN1363654A (zh) * | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp-1(7-36)的基因工程菌以及生产glp-1(7-36)的方法 |
EP1430115A1 (de) | 2001-07-27 | 2004-06-23 | Arhus Amt | Immortalisierte stammzellen |
US7576050B2 (en) | 2001-07-31 | 2009-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
US20040143104A1 (en) * | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
US7238663B2 (en) | 2001-08-28 | 2007-07-03 | Eli Lilly And Company | Pre-mixes of GLP-1 and basal insulin |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
DE60217918T2 (de) * | 2001-12-29 | 2007-11-15 | Novo Nordisk A/S | Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors |
CA2468700A1 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
CA2497794A1 (en) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
JP4548335B2 (ja) | 2003-03-07 | 2010-09-22 | 味の素株式会社 | 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤 |
JP2007501811A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。 |
CN100580087C (zh) | 2003-10-10 | 2010-01-13 | 诺和诺德医疗保健公司 | 肽的缀合 |
BRPI0417684A (pt) | 2003-12-18 | 2007-03-20 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
CA2849552A1 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
KR20070004078A (ko) | 2004-03-31 | 2007-01-05 | 센토코 인코포레이티드 | 인간 glp-1 모방체, 조성물, 방법 및 용도 |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
US20090175795A1 (en) | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
PT1767545E (pt) | 2005-09-22 | 2010-02-05 | Biocompatibles Uk Ltd | Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase |
EP1854455B1 (de) | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
EP1972349A1 (de) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP1975176A1 (de) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP2163243A1 (de) | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern |
-
2006
- 2006-05-10 EP EP06009678A patent/EP1854455B1/de not_active Not-in-force
- 2006-05-10 DE DE602006009631T patent/DE602006009631D1/de not_active Expired - Fee Related
- 2006-05-10 AT AT06009678T patent/ATE444741T1/de not_active IP Right Cessation
-
2007
- 2007-04-27 PT PT07724702T patent/PT2015736E/pt unknown
- 2007-04-27 EP EP09014514A patent/EP2174655A1/de not_active Withdrawn
- 2007-04-27 CA CA002649902A patent/CA2649902A1/en not_active Abandoned
- 2007-04-27 WO PCT/EP2007/003775 patent/WO2007128443A2/en active Application Filing
- 2007-04-27 US US12/300,087 patent/US8790705B2/en not_active Expired - Fee Related
- 2007-04-27 AU AU2007247511A patent/AU2007247511B2/en not_active Ceased
- 2007-04-27 ES ES07724702T patent/ES2363810T3/es active Active
- 2007-04-27 CN CNA2007800260098A patent/CN101489539A/zh active Pending
- 2007-04-27 DE DE602007013385T patent/DE602007013385D1/de active Active
- 2007-04-27 PL PL07724702T patent/PL2015736T3/pl unknown
- 2007-04-27 AT AT07724702T patent/ATE502628T1/de active
- 2007-04-27 EP EP07724702A patent/EP2015736B1/de not_active Not-in-force
- 2007-04-27 DK DK07724702.1T patent/DK2015736T3/da active
- 2007-04-27 JP JP2009508185A patent/JP5209608B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-16 US US13/653,277 patent/US20140105991A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PT2015736E (pt) | 2011-05-30 |
EP1854455B1 (de) | 2009-10-07 |
ATE502628T1 (de) | 2011-04-15 |
CA2649902A1 (en) | 2007-11-15 |
EP1854455A1 (de) | 2007-11-14 |
WO2007128443A2 (en) | 2007-11-15 |
EP2015736B1 (de) | 2011-03-23 |
JP5209608B2 (ja) | 2013-06-12 |
DE602006009631D1 (de) | 2009-11-19 |
ES2363810T3 (es) | 2011-08-17 |
CN101489539A (zh) | 2009-07-22 |
PL2015736T3 (pl) | 2011-09-30 |
AU2007247511B2 (en) | 2012-12-06 |
AU2007247511A1 (en) | 2007-11-15 |
DK2015736T3 (da) | 2011-06-14 |
DE602007013385D1 (de) | 2011-05-05 |
JP2009536166A (ja) | 2009-10-08 |
WO2007128443A3 (en) | 2008-05-22 |
EP2015736A2 (de) | 2009-01-21 |
US8790705B2 (en) | 2014-07-29 |
EP2174655A1 (de) | 2010-04-14 |
US20140105991A1 (en) | 2014-04-17 |
US20100068289A1 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE444741T1 (de) | Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung | |
ATE455783T1 (de) | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung | |
CR10852A (es) | Compuestos biciclicos y su uso como anti-diabeticos | |
WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
WO2007048122A3 (en) | Antibody-based therapeutics with enhanced adcc activity | |
WO2010049678A3 (en) | Treatment of energy utilization diseases | |
GB2450056A (en) | CD47 Related compositions and methods for treating immunological diseases and disorders | |
WO2007022470A3 (en) | Methods and compositions for treating neurological disease | |
GT200800278A (es) | Moleculas de enlace multivalente y sus aplicaciones terapeuticas | |
IL182116A0 (en) | Nanobodies tm against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neural diseases such as alzheimer's disease | |
IL195156A (en) | Polypeptides containing human igf-1 protein precursor, their use in the preparation of drugs for the treatment of musculoskeletal disease, nucleic acid encoding the above polypeptides, a vector containing the above nucleic acid and a cell transfected with the above vector | |
WO2009017655A3 (en) | Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof | |
WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
CL2007003733A1 (es) | Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi | |
DK1745069T3 (da) | Terapeutisk anvendelse af vækstfaktoren NSG33 | |
EP1790720A4 (de) | Polypeptid mit der aktivität einer ungesättigten omega-3-fettsäure, für das polypeptid codierendes polynukleotid und verwendung davon | |
WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
DK2407536T3 (da) | Adp-ribosyltransferase-fusionsvariantproteiner | |
DE60304695D1 (de) | 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN | |
DE602007011037D1 (de) | Achsensteuerung bei der herstellung von torischen kontaktlinsen | |
WO2005118920A3 (en) | Methods for generating neuronal cells from human embryonic stem cells and uses thereof | |
MX2010005205A (es) | Isoformas de neurregulina solubles activas modificadas postraduccionalmente. | |
WO2008154516A3 (en) | Btnl2 fusion protein for t-cell activity modulation | |
WO2009017719A8 (en) | Modulators of ccr9 receptor and methods of use thereof | |
ATE399803T1 (de) | Gleichmässig hinhaltend ein aminosäurederivat freisetzendes polymer, kosmetikum und faserkonstrukt mit dem polymer, herstellungsverfahren dafür und regenerationsverfahren dafür |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |